Health Care & Life Sciences » Biotechnology | Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc. | Ownership

Companies that own Actinium Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
DLD Asset Management LP
3,298,193
2.99%
-250,000
0.27%
06/30/2018
The Vanguard Group, Inc.
2,405,889
2.18%
-61,941
0%
06/30/2018
Credit Suisse Securities (USA) LLC (Broker)
1,310,213
1.19%
500,013
0%
06/30/2018
Sio Capital Management LLC
872,406
0.79%
-203,794
0.31%
06/30/2018
BlackRock Fund Advisors
469,578
0.43%
-165,422
0%
06/30/2018
Renaissance Technologies LLC
387,500
0.35%
359,205
0%
06/30/2018
Worth Venture Partners LLC
354,556
0.32%
-26,875
0.24%
06/30/2018
Geode Capital Management LLC
312,355
0.28%
121,106
0%
06/30/2018
Apo Asset Management GmbH
192,568
0.17%
192,568
0.01%
06/29/2018
Bridgeway Capital Management, Inc.
172,300
0.16%
0
0%
06/30/2018

About Actinium Pharmaceuticals

View Profile
Address
275 Madison Avenue
New York New York 10016
United States
Employees -
Website http://www.actiniumpharmaceuticals.com
Updated 07/08/2019
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.